TABLE 2

Absorbed Doses for ⁹⁰Y, Renal Protection,^* Radionuclide Used for Theranostics, and Method Used for Dosimetry

			Absorbed dose (Gy/GBq)
Organ or lesion	No. of patients	Renal protection	Median	Range	Mean ± SD	Radionuclide for theranostics	Method	Reference
Red marrow	18	No			0.03 ± 0.01	¹¹¹In	Blood	20
	5	No	0.17	0.15–0.19	0.17 ± 0.02	¹¹¹In	Blood	43
	8	Yes			0.06 ± 0.02	⁸⁶Y	Blood	47
Kidney	18	No			3.3 ± 2.2	¹¹¹In	Planar	20
	5	No	3.0	1.9–3.6	2.8 ± 0.6	¹¹¹In	Planar	43
	4	No	4.8	3.1–5.2	4.4 ± 1.0	⁸⁶Y	PET	44
	6	Yes	1.8	1.4–2.0	1.7 ± 0.3
	17	Yes	3.8	1.9–7.6		¹¹¹In	SPECT	45
	8	Yes		0.6–2.8	1.7 ± 0.9	⁸⁶Y	PET	47
	8	No			6.1	¹¹¹In	Planar	56
Tumor	18	No	9.6	1.4–31	10.1 ± 7.5	¹¹¹In	Planar	20
	5	No	12.2	2.4–41.7	16.0 ± 14.6	¹¹¹In	Planar	43
	4	No			2.0 ± 0.7	⁸⁶Y	PET	44
	6	Yes			2.1 ± 0.7
	24^†			0.4–16.5
	17	Yes	3.8	0.9–5.4		¹¹¹In	SPECT	45
	8	Yes		2.1–29.5	9.0 ± 6.6	⁸⁶Y	PET	47